Pharmacokinetics of a C5a receptor antagonist in the rat after different sites of enteral administration

European Journal of Pharmaceutical Sciences

Volumn 33, Issue 4-5, 2008, Pages 390-398

  Morgan, Michael ^a   Bulmer, Andrew C ^a   Woodruff, Trent M ^a   Proctor, Lavinia M ^a   Williams, Hua M ^a   Stocks, Shelli Z ^a   Pollitt, Sandra ^a   Taylor, Stephen M ^a   Shiels, Ian A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

C5a receptor antagonist; Chitosan; Enteral administration; Peptide absorption

Indexed keywords

CHITOSAN; COMPLEMENT COMPONENT C5A RECEPTOR ANTAGONIST; PMX 53; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; MUCOSA; NONHUMAN; PORTAL VEIN BLOOD; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; BILE; COMPLEMENT C5A; DRUG CARRIERS; FEMALE; INJECTIONS, INTRAVENOUS; PEPTIDES, CYCLIC; RATS; RATS, WISTAR;

EID: 41349101709     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2008.01.009     Document Type: Article

References (25)

1. Arumugam T.V., Shiels I.A., Woodruff T.M., Reid R.C., Fairlie D.P., and Taylor S.M. Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine. J. Surg. Res. 103 (2002) 260-267
2. Arumugam T.V., Shiels I.A., Strachan A.J., Abbenante G., Fairlie D.P., and Taylor S.M. A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int. 63 (2003) 134-142
3. Arumugam T.V., Woodruff T.M., Stocks S.Z., Proctor L.M., Pollitt S., Shiels I.A., Reid R.C., Fairlie D.P., and Taylor S.M. Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats. J. Hepatol. 40 (2004) 934-941
4. de Boer A.G., Moolenaar F., de Leede L.G., and Breimer D.D. Rectal drug administration: clinical pharmacokinetic considerations. Clin. Pharmacokinet. 7 (1982) 285-311
5. Finch A.M., Wong A.K., Paczkowski N.J., Wadi S.K., Craik D.J., Fairlie D.P., and Taylor S.M. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J. Med. Chem. 42 (1999) 1965-1974
6. Girardi G., Berman J., Redecha P., Spruce L., Thurman J.M., Kraus D., Hollmann T.J., Casali P., Caroll M.C., Wetsel R.A., Lambris J.D., Holers V.M., and Salmon J.E. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J. Clin. Invest. 112 (2003) 1644-1654
7. Grant E.P., Picarella D., Burwell T., Delaney T., Croci A., Avitahl N., Humbles A.A., Gutierrez-Ramos J.C., Briskin M., Gerard C., and Coyle A.J. Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis. J. Exp. Med. 196 (2002) 1461-1471
8. Guo J., Ping Q., Jiang G., Dong J., Qi S., Feng L., Li Z., and Li C. Transport of leuprolide across rat intestine, rabbit intestine and Caco-2 cell monolayer. Int. J. Pharm. 278 (2004) 415-422
9. Harkin D.W., Romaschin A., Taylor S.M., Rubin B.B., and Lindsay T.F. Complement C5a receptor antagonist attenuates multiple organ injury in a model of ruptured abdominal aortic aneurysm. J. Vasc. Surg. 39 (2004) 196-206
10. Hinchcliffe M., Jabbal-Gill I., and Smith A. Effect of chitosan on the intranasal absorption of salmon calcitonin in sheep. J. Pharm. Pharmacol. 57 (2005) 681-687
11. Huber-Lang M.S., Riedeman N.C., Sarma J.V., Younkin E.M., McGuire S.R., Laudes I.J., Lu K.T., Guo R.F., Neff T.A., Padgaonkar V.A., Lambris J.D., Spruce L., Mastellos D., Zetoune F.S., and Ward P.A. Protection of innate immunity by C5aR antagonist in septic mice. FASEB J. 16 (2002) 1567-1574
12. March D.R., Proctor L.M., Stoermer M.J., Sbaglia R., Abbenante G., Reid R.C., Woodruff T.M., Wadi K., Paczkowski N., Tyndall J.D., Taylor S.M., and Fairlie D.P. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity. Mol. Pharmacol. 65 (2004) 868-879
13. Reddy S.M., Sinha V.R., and Reddy D.S. Novel oral colon-specific drug delivery systems for pharmacotherapy of peptide and nonpeptide drugs. Drugs Today (Barc.) 35 (1999) 537-580
14. Senel S., Kremer M.J., Kas S., Wertz P.W., Hincal A.A., and Squier C.A. Enhancing effect of chitosan on peptide drug delivery across buccal mucosa. Biomaterials 21 (2000) 2067-2071
15. Sewell D.L., Nacewicz B., Liu F., Macvilay S., Erdei A., Lambris J.D., Sandor M., and Fabry Z. Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist. J. Neuroimmunol. 155 (2004) 55-63
16. Smith J., Wood E., and Dornish M. Effect of chitosan on epithelial cell tight junctions. Pharm. Res. 21 (2004) 43-49
17. Strachan A.J., Woodruff T.M., Haaima G., Fairlie D.P., and Taylor S.M. A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats. J. Immunol. 164 (2000) 6560-6565
18. Strachan A.J., Shiels I.A., Reid R.C., Fairlie D.P., and Taylor S.M. Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist. Br. J. Pharmacol. 134 (2001) 1778-1786
19. Thanou M., Florea B.I., Langemeyer M.W., Verhoef J.C., and Junginger H.E. N-trimethylated chitosan chloride (TMC) improves the intestinal permeation of the peptide drug buserelin in vitro (Caco-2 cells) and in vivo (rats). Pharm. Res. 17 (2000) 27-31
20. Wang M., and Dickinson R.G. Bile duct ligation promotes covalent drug-protein adduct formation in plasma but not in liver of rats given zomepirac. Life Sci. 68 (2000) 525-537
21. Woodruff T.M., Strachan A.J., Dryburgh N., Shiels I.A., Reid R.C., Fairlie D.P., and Taylor S.M. Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arthritis Rheum. 46 (2002) 2476-2485
22. Woodruff T.M., Arumugam T.V., Shiels I.A., Reid R.C., Fairlie D.P., and Taylor S.M. A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J. Immunol. 171 (2003) 5514-5520
23. Woodruff T.M., Arumugam T.V., Shiels I.A., Reid R.C., Fairlie D.P., and Taylor S.M. Protective effects of a potent C5a receptor antagonist on experimental acute limb ischemia-reperfusion in rats. J. Surg. Res. 116 (2004) 81-90
24. Woodruff T.M., Pollitt S., Proctor L.M., Stocks S.Z., Manthey H.D., Williams H.M., Mahadevan I.B., Shiels I.A., and Taylor S.M. Increased potency of a novel C5a receptor antagonist in a rat model of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 314 (2005) 811-817
25. Woodruff T.M., Crane J.W., Proctor L.M., Buller K.M., Shek A.B., de Vos K., Pollitt S., Williams H.M., Shiels I.A., Monk P.N., and Taylor S.M. Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J. 20 (2006) 1407-1417